Fusion Pharmaceuticals Q2 EPS $(0.38) Beats $(0.39) Estimate, Sales $34.00K Miss $80.00K Estimate
Portfolio Pulse from Benzinga Newsdesk
Fusion Pharmaceuticals (NASDAQ:FUSN) reported Q2 losses of $(0.38) per share, beating the analyst consensus estimate of $(0.39) by 2.56 percent. However, the company's quarterly sales of $34.00 thousand missed the analyst consensus estimate of $80.00 thousand by 57.50 percent, marking a 94.04 percent decrease from the same period last year.
August 08, 2023 | 11:07 am
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
Fusion Pharmaceuticals reported better than expected Q2 EPS but significantly missed sales estimates. This could lead to mixed reactions in the market.
Fusion Pharmaceuticals reported a better than expected EPS, which could be seen as a positive by investors. However, the significant miss on sales estimates could be a cause for concern, potentially leading to a mixed market reaction.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100